Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma HELP
Based on 58,025 articles published since 2009
|||| 52 

These are the 58025 published articles about Melanoma that originated from Worldwide during 2009-2019.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
201 Editorial Are PD-1 antibodies safe for use in metastatic uveal melanoma? 2017

Tsai, Katy K / Algazi, Alain P. ·Melanoma Center, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA. ·Melanoma Manag · Pubmed #30190908.

ABSTRACT: -- No abstract --

202 Editorial Melanoma treatment guided by a panel of microRNA biomarkers. 2017

Stark, Mitchell S. ·Dermatology Research Centre, The University of Queensland Diamantina Institute at the Translational Research Institute, Brisbane, Queensland, Australia. ·Melanoma Manag · Pubmed #30190907.

ABSTRACT: -- No abstract --

203 Editorial When to consider alternatives to front-line immune therapies in metastatic melanoma. 2017

Wang, Daniel Y / Johnson, Douglas B. ·Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. ·Melanoma Manag · Pubmed #30190906.

ABSTRACT: -- No abstract --

204 Editorial Are we entering the era of combination therapy for melanoma? 2017

Cohen, Justine V / Sullivan, Ryan J. ·Cancer Center - Massachusetts General Hospital, Boston, MA, USA. ·Melanoma Manag · Pubmed #30190901.

ABSTRACT: -- No abstract --

205 Editorial Is the Prognosis of Uveal Melanoma Improving? 2017

Suzuki, Shigenobu. · ·Nippon Ganka Gakkai Zasshi · Pubmed #30074748.

ABSTRACT: -- No abstract --

206 Editorial Dermoscopy - Not just for diagnosis and not just for Dermatologists ! 2017

Sonthalia, S / Errichetti, E. ·Department of Dermatology and Dermatosurgery, The Skin Clinic and Research Centre, Sushant Lok-1, Gurugram-122009, Haryana, India. · Dermatologist and Venereologist, Institute of Dermatology, University Hospital "Santa Maria della Misericordia", Udine, Italy. ·Kathmandu Univ Med J (KUMJ) · Pubmed #29446353.

ABSTRACT: -- No abstract --

207 Editorial Prognostication for Uveal Melanoma: Are Two Tests Better than One? 2017

Bellerive, Claudine / Grossniklaus, Hans E / Singh, Arun D. ·Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA. · Department of Ophthalmology and Pathology, Emory University, Atlanta, Georgia, USA. ·Ocul Oncol Pathol · Pubmed #29344485.

ABSTRACT: -- No abstract --

208 Editorial Is There an Increased Prevalence of Asteroid Hyalosis in Eyes with Uveal Melanoma? A Histopathologic Study. 2017

Burris, Christopher K H / Azari, Amir A / Kanavi, Mozhgan R / Dubielzig, Richard R / Lee, Vivian / Gottlieb, Justin L / Potter, Heather D / Kim, Kyungmann / Raven, Meisha L / Rodriguez, Maria E / Reddy, Devasis N / Albert, Daniel M. ·Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin, USA. · Ocular Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. · Comparative Ocular Pathology Laboratory of Wisconsin, University of Wisconsin School of Veterinary Medicine, Madison, Wisconsin, USA. · Department of Biostatistics and Informatics, University of Wisconsin, Madison, Wisconsin, USA. · Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA. ·Ocul Oncol Pathol · Pubmed #29344477.

ABSTRACT: During the planning meeting for the Collaborative Ocular Melanoma Study (COMS) prior to the start of patient recruitment in 1986, there was an interest expressed in determining whether a relationship existed between the presence of uveal melanoma (UM) and asteroid hyalosis (AH). To answer this question, the ophthalmic examination form (unlike the pathology form for enucleated eyes) for each COMS patient asked whether AH was present or not. Though an increased prevalence was not found, this result was never published. A recent unpublished study at the University of Wisconsin School of Veterinary Medicine indicated a higher prevalence of AH in canine eyes with UM when compared to control eyes (without tumor) enucleated for goniodysgenesis. This further increased our interest in revisiting the published literature, clinical records, and histopathology slides of the enucleated eyes from the COMS study, as well as the histopathology slides on file in the University of Wisconsin Eye Pathology Laboratory. While cases with both AH and UM were occasionally encountered in the literature, clinically, we could not find a previous study focusing on these two processes. This study was conducted to explore whether such an association exists.

209 Editorial What is changing in the adjuvant treatment of melanoma? 2017

Ascierto, Paolo A / Palmieri, Giuseppe / Gogas, Helen. ·Paolo A. Ascierto: Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy. ·Oncotarget · Pubmed #29340009.

ABSTRACT: -- No abstract --

210 Editorial Editorial: Self-Eating on Demand: Autophagy in Cancer and Cancer Therapy. 2017

Lane, Jon D / Agostinis, Patrizia. ·Cell Biology Laboratories, School of Biochemistry, University of Bristol, Bristol, United Kingdom. · Cell Death Research and Therapy (CDRT) Lab, Department of Cellular Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium. ·Front Oncol · Pubmed #29270388.

ABSTRACT: -- No abstract --

211 Editorial Effectiveness of the Mohs and Close Technique in Increasing the Efficiency of a Mohs Micrographic Surgery. 2017

Konda, Sailesh / Francis, Joseph / Patel, Vishal A. · ·J Drugs Dermatol · Pubmed #29240868.

ABSTRACT: Editor's note: JDD welcomes Letters to the Editor that discuss controversy surrounding a recently published article. Letters being considered for publication may be sent to the authors of the original article, who may be given the opportunity to reply. Letters will be published at the discretion of the Editors.

212 Editorial Conditional survival estimates for cancer patients. 2017

Haydu, Lauren E / Scolyer, Richard A / Thompson, John F. ·John F. Thompson: Melanoma Institute Australia, The University of Sydney, and Sydney Medical School, The University of Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Camperdown, NSW, Australia. ·Oncotarget · Pubmed #29156671.

ABSTRACT: -- No abstract --

213 Editorial Targeted treatment of advanced NRAS-mutated melanoma. 2017

Koelblinger, Peter / Dummer, Reinhard. ·Reinhard Dummer: Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland. ·Oncotarget · Pubmed #29156659.

ABSTRACT: -- No abstract --

214 Editorial Adjuvant Melanoma Therapy - Head-Spinning Progress. 2017

Schuchter, Lynn M. ·From the University of Pennsylvania Abramson Cancer Center, Philadelphia. ·N Engl J Med · Pubmed #29117487.

ABSTRACT: -- No abstract --

215 Editorial The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. 2017

Masucci, Giuseppe V / Cesano, Alessandra / Eggermont, Alexander / Fox, Bernard A / Wang, Ena / Marincola, Francesco M / Ciliberto, Gennaro / Dobbin, Kevin / Puzanov, Igor / Taube, Janis / Wargo, Jennifer / Butterfield, Lisa H / Villabona, Lisa / Thurin, Magdalena / Postow, Michael A / Sondel, Paul M / Demaria, Sandra / Agarwala, Sanjiv / Ascierto, Paolo A. ·Department of Oncology-Pathology, Karolinska Institutet, 171 76, Stockholm, Sweden. Giuseppe.Masucci@ki.se. · NanoString, Inc, 530 Fairview Avenue N, Seattle, WA, 98109, USA. · Gustave Roussy Cancer Institute, 114 Rue Edouard Vaillant, Villejuif/Paris-Sud, France. · Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan, Portland, OR, 97213, USA. · Research Branch, Division Chief of Translational Medicine at Sidra Medical and Research Center, Doha, Qatar. · Abbvie Corp. Redwood City, California, IL, 94063, USA. · IRCCS IRCCS Istituto Nazionale Tumori Regina Elena, via Elio Chianesi 53, Rome, Italy. · Department of Epidemiology and Biostatistics, College of Public Health, The University of Georgia, 101 Buck Road, Athens, GA, 30602, USA. · Melanoma Section Department of Medicine, CSC Building Roswell Park Cancer Institute, Elm & Carlton Streets, 915, Buffalo, NY, 14263, USA. · Department of Dermatology, Johns Hopkins University SOM, 600N. Wolfe Street Blalock 907, Baltimore, MD, 21287, USA. · Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Department of Medicine, Surgery and Immunology, University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Pittsburgh, PA, 15213, USA. · Department of Oncology-Pathology, Karolinska Institutet, 171 76, Stockholm, Sweden. · National Cancer Institute, Cancer Diagnosis Program, DCTD, National Institutes of Health, 9609 Medical Center Drive, Bethesda, MD, 20892, USA. · Melanoma and Immunotherapy Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. · Weill Cornell Medical College, New York, NY, USA. · Sarcoma Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. · Departments of Pediatrics, Human Oncology and Genetics, University of Wisconsin, 4159 WIMR Building, 1111 Highland Ave, Madison, WI, USA. · Department of Radiation Oncology and Pathology, Weill Cornell Medicine, 1300 York Avenue, Box 169, New York, NY, 10065, USA. · St. Luke's University Hospital and Temple University, Bethlehem, USA. · Melanoma. Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione "G. Pascale", Via Mariano Semmola, 80131, Naples, Italy. paolo.ascierto@gmail.com. ·J Transl Med · Pubmed #29100546.

ABSTRACT: Immunotherapies have emerged as one of the most promising approaches to treat patients with cancer. Recently, the entire medical oncology field has been revolutionized by the introduction of immune checkpoints inhibitors. Despite success in a variety of malignancies, responses typically only occur in a small percentage of patients for any given histology or treatment regimen. There are also concerns that immunotherapies are associated with immune-related toxicity as well as high costs. As such, identifying biomarkers to determine which patients are likely to derive clinical benefit from which immunotherapy and/or be susceptible to adverse side effects is a compelling clinical and social need. In addition, with several new immunotherapy agents in different phases of development, and approved therapeutics being tested in combination with a variety of different standard of care treatments, there is a requirement to stratify patients and select the most appropriate population in which to assess clinical efficacy. The opportunity to design parallel biomarkers studies that are integrated within key randomized clinical trials could be the ideal solution. Sample collection (fresh and/or archival tissue, PBMC, serum, plasma, stool, etc.) at specific points of treatment is important for evaluating possible biomarkers and studying the mechanisms of responsiveness, resistance, toxicity and relapse. This white paper proposes the creation of a network to facilitate the sharing and coordinating of samples from clinical trials to enable more in-depth analyses of correlative biomarkers than is currently possible and to assess the feasibilities, logistics, and collated interests. We propose a high standard of sample collection and storage as well as exchange of samples and knowledge through collaboration, and envisage how this could move forward using banked samples from completed studies together with prospective planning for ongoing and future clinical trials.

216 Editorial Futures. 2017

Arnheiter, Heinz. · ·Pigment Cell Melanoma Res · Pubmed #29094508.

ABSTRACT: -- No abstract --

217 Editorial Personalized melanoma genomic risk information:perception of shared risk initiates sharing with family. 2017

Robinson, J K / Spring, B. ·Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A. · Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A. ·Br J Dermatol · Pubmed #29052877.

ABSTRACT: -- No abstract --

218 Editorial Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma. 2017

Carlino, Matteo S / Sandhu, Shahneen. ·Matteo S. Carlino, Westmead and Blacktown Hospitals and University of Sydney, Sydney, New South Wales, Australia · and Shahneen Sandhu, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia. ·J Clin Oncol · Pubmed #29048973.

ABSTRACT: -- No abstract --

219 Editorial The 'All-or-None Law' Applied to the Vertical Growth Phase of Cutaneous Malignant Melanoma. 2017

Roncati, Luca / Vergari, Benedetto / Del Gaudio, Antonio. ·Department of Diagnostic and Clinical Medicine and of Public Health, Institute of Pathology, University of Modena and Reggio Emilia, Modena, Italy. · Department of Legal Medicine, Postgraduate School in Forensics, University of Bologna, Bologna, Italy. · Department of Surgical Disciplines, American College of Surgeons, University of Bologna, Bologna, Italy. ·Chonnam Med J · Pubmed #29026715.

ABSTRACT: -- No abstract --

220 Editorial Whither melanoma in Australia? 2017

Smithers, B Mark / Dunn, Jeff / Soyer, H Peter. ·University of Queensland, Brisbane, QLD m.smithers@uq.edu.au. · Institute for Resilient Regions, University of Southern Queensland, Toowoomba, QLD. · Princess Alexandra Hospital, Brisbane, QLD. ·Med J Aust · Pubmed #29020902.

ABSTRACT: -- No abstract --

221 Editorial Adjuvant Ipilimumab for Melanoma-The $1.8 Million per Patient Regimen. 2017

Goldstein, Daniel A. ·Davidoff Cancer Center, Rabin Medical Center, Petach Tikvah, Israel · Winship Cancer Institute, Emory University, Atlanta, Georgia ·JAMA Oncol · Pubmed #28983562.

ABSTRACT: -- No abstract --

222 Editorial Is melanoma treatment failing national standards? 2017

Simcock, Jeremy. ·Plastic Surgery, University of Otago, Christchurch. ·N Z Med J · Pubmed #28934763.

ABSTRACT: -- No abstract --

223 Editorial Clinical and pathologic factors associated with deep transection of biopsies of invasive melanoma. 2017

Woodcock, Jamie L / Eyre, Zachary W / Stoddard, Gregory J / Callis Duffin, Kristina / Bowen, Anneli R. ·Department of Dermatology, University of Utah, Salt Lake City, Utah. Electronic address: jamie.woodcock@hsc.utah.edu. · University of Utah, School of Medicine, Salt Lake City, Utah. · Department of Internal Medicine, University of Utah, Salt Lake City, Utah. · Department of Dermatology, University of Utah, Salt Lake City, Utah. ·J Am Acad Dermatol · Pubmed #28917460.

ABSTRACT: -- No abstract --

224 Editorial The Importance of Early Recognition of Skin Cancer. 2017

Farberg, Aaron S / Rigel, Darrell S. ·Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th Street Floor 5, New York, NY 10029, USA. Electronic address: aaron.farberg@gmail.com. · Department of Dermatology, NYU School of Medicine, 35 East 35th Street Suite 208, New York, NY 10016, USA. Electronic address: darrell.rigel@gmail.com. ·Dermatol Clin · Pubmed #28886816.

ABSTRACT: -- No abstract --

225 Editorial "If you want to go far, go together". 2017

Aplin, Andrew E. ·Pigment Cell & Melanoma Research. ·Pigment Cell Melanoma Res · Pubmed #28834183.

ABSTRACT: -- No abstract --

Back · Next